MIDDLETON, Wis.--(BUSINESS WIRE)--Zurex Pharma, Inc. (Zurex), a life sciences and medical technology company with a novel antimicrobial technology platform, announced today it has raised more than $6 million in an initial close of a Series C financing, with significant participation from current shareholders and substantial contributions from new investors. Zurex intends to use the funds to support pivotal Phase III clinical trials of its lead compound and for general corporate and working capital purposes.
According to a report from the US Department of Health and Human Services, 1 in 20 patients have a health care-associated infection at any given time, and these infections are responsible for approximately $28 billion to $32 billion in preventable health care costs each year. Zurex is focused on the development of its proprietary antimicrobial platform and novel product candidates designed to prevent or minimize healthcare acquired infections that may occur in a variety of inpatient, ambulatory and home care settings.
“The Zurex team is excited about initiating the final stages of clinical development with our lead product (ZuraPrep™) designed to help prevent surgical site infections, and greatly appreciates the strong show of confidence and support from both our current and new shareholders,” said Carmine Durham, President and CEO of Zurex.
About Zurex Pharma
Zurex Pharma, Inc. is a life sciences and medical technology company with a novel antimicrobial technology platform. The company's mission is to develop and commercialize a portfolio of innovative antimicrobial products designed to prevent health care-associated infections with a focus on surgical site wounds and catheter-related infections. For more information, please visit www.zurexpharma.com
